Prof. h.c.* Dr. med. vet. Farid SaadPrinzenallee 2813359 BerlinGermanyEmail: Farid.Saad@bayerhealthcare.com

Curriculum vitae

Dec. 23rd, 1953 born in Alexandria, Egypt

1972 – 1973 3 semesters studies of human medicine at the University of Hamburg

1973 – 1976 studies of veterinary medicine and preclinical exams at the Free University of Berlin

1976 – 1980 studies of veterinary medicine, state exams, graduation and PhD at the Veterinary University of Hannover

- during this time several working periods with equine practitioners in the U.S.A. –

1980 – 1987 veterinary surgeon, employed by Dr. G. Kubitza in Hamburg, specialisation in race horses and equine reproduction

1988 – 1990 sales representative and member of the sales force of Hoechst AG

1990 – 1998 product manager, then marketing director and international marketing and sales director, Ferring GmbH in Kiel; specialist for reproductive endocrinology, pediatric endocrinology, and andrology

1998 team leader reproductive medicine, Organon GmbH, Oberschleissheim

1998 – 2001 leader of clinical development andrology, Jenapharm, Jena;

specialist in endocrinology of aging, male aging, male hormonal fertility control

since May 2001 corporate strategic marketing Schering AG, Berlin; leader of product group ”Male Health Care“

2005-12-28 Honorary professorship in clinical research and endocrinology at Gulf Medical College, Ajman, United Arab Emirates

2006-08-10 Honorary professorship at Men’s Health Reproduction Study Center, Hang Tuah University, Surabaya, Indonesia

Citizenship : German

*Gulf Medical University School of Medicine, Ajman, UAE

Publications

1. Th. Willmen, H. Sieme, H. Merkt, F. SaadSamenkonservierung und hormonelle Beeinflussung der Samenqualitaet beim Kamel(Semen preservation and hormonal effects upon semen quality in camels)Reproduction in Domestic Animals, Vol. 27 (4), 174, 1992 (Abstract)

2. M. Oettel, W. Elger, D. Fauteck, T. Graeser, D. Huebler, A. Mueller, V. Patchev, F. SaadTrends and perspectives of drug development for hormone replacement in women and menInt. Symposium on molecular and clinical aspects of the regulation of ovarian function: Impact on the reproductive health of women, New Delhi, October 1999 (Abstract)

3. M. Oettel, B. Allolio, W. Arlt, T. Graeser, D. Huebler, V. Patchev, F. Saad, U. Schumacher, B. WinkelmannHormone Replacement vs. Hormone Displacement in the Aging MaleThe Aging Male, Vol. 3 (Suppl. 1), 27, 2000 (Abstract)

4. F. SaadThe Aging Male Project – Research and Development at Jenapharm8th National Congress of Indonesian Society of Andrology and International Symposium on New Perspectives of Andrology in Human Reproduction, Padang, Indonesia, 2000 (Abstract)

5. F. Saad, L.A.J. HeinemannStandardized Aging Males‘ Symptoms Scale (AMS): Reliability across culturesThe Aging Male, Vol. 4 (Suppl. 1), 94, 2001 (Abstract)

6. L.A.J. Heinemann, F. Saad, K. Thiele, S. Wood-DauphineeThe Aging Males Symptoms (AMS) rating scale: Cultural and linguistic validation into EnglishThe Aging Male, Vol. 4 (1): 14-22, 2001

7. F. Saad, D. Huebler, M. Ernst, U. Mellinger, M. Oettel, A. Christoph, M. Schubert, W. Krone, F. JockenhoevelA novel injectable testosterone undecanoate (TU) does not lead to supraphysiological testosterone concentrations in the treatment of male hypogonadismVII International Congress on Andrology, Montréal, Canada, 2001 J Androl May/June 2001, Suppl., pg 132 (Abstract)

8. P. Poellaenen, K. Haerkoenen, J. Maekinen, K. Irjala, F. Saad, D. Huebler, M. Oettel, M. Koskenvuo, I. HuhtaniemiRelationships of Sex Hormones, Androgen Receptor CAG Repeat Number and Symptoms in the Aging MalesEuropean Federation of Endocrine Societies. 2001 (Abstract)

9. P. Poellaenen, F. Saad, M. Oettel, D. Huebler, J. Maekinen, I. HuhtaniemiDetermination of the Frequency and Stability of Andropausal Symptoms among 15900 40-70-Year-Old MenBaltic Sea Congress on Gynaecology, 2001 (Abstract)

10. F. SaadThe Aging Male Project – Research and Development at JenapharmMedical Journal of Indonesia, 2001

11. C. Oxynos, J.M. Phillipps, F. Saad, M. Oettel, F.C.W. WuDehydroepiandrosterone (DHEA) as a potential novel oral androgen replacement in male hypogonadism – a pharmacokinetic and pharmacodynamic study84th Annual Meeting of the Endocrine Society, San Francisco, June 19-22, 2002 (Abstract)

12. M.C. Meriggiola, A. Costantino, F. Saad, A.M. Perrone, S. Cerpolini. W.J. Bremner, G. PelusiEight-weekly injections of norethisterone enanthate (NETE) plus testosterone undecanoate (TU) induces profound sperm suppression in men84th Annual Meeting of the Endocrine Society, San Francisco, June 19-22, 2002 (Abstract)

13. P. Poellaenen, K. Haerkoenen, J. Maekinen, K. Irjala, F. Saad, D. Huebler, M. Oettel, M. Koskenvuo, I. HuhtaniemiRelationships of sex hormones, androgen receptor CAG repeat number and symptoms in the aging malesEuropean Federation of Endocrine Societies 2002 (Abstract)

14. L.A.J. Heinemann, F. Saad, P. PoellaenenMeasurement of quality of life specific for aging malesIn: H.P.G. Schneider, ed.: Hormone replacement therapy and quality of life, Parthenon, New York and London, 2002

15. A.A. Yassin, F. Saad, H.E. DiedeKombinationstherapie bei erektiler Dysfunktion mit Testosteron und Tadalafil bei hypogonadalen Patienten, die auf Tadalafil als Monotherapie nicht ansprechenBlickpunkt DER MANN 2(1): 37-39, 2003

16. L.A.J. Heinemann, F. Saad, T. Zimmermann, A. Novak, E. Myon, X. Badia, P. Potthoff, G. T’Sjoen, P. Poellaenen, N.P. Goncharov, S. Kim, C. GiroudetThe Aging Males‘ Symptoms (AMS) scale: Update and compilation of international versionsHealth and Quality of Life Outcomes 1:15, 2003

17. K. Heinemann, F. SaadSweating attacks: Key symptom in menopausal transition only for women?Eur Urol 44: 583-587, 2003

18. A Yassin, H.E. Diede, F. Saad, A. TraishCombination therapy of tadalafil & testosterone in hypogonadal non-responders

6th Congress of the European Society for Sexual Medicine, Istanbul, Turkey, November 16-19, 2003Int J Impot Res 15, Suppl. 6: S27, 2003

19. Haerkoenen K, Huhtaniemi I, Maekinen J, Huebler D, Irjala K, Koekenvuo M, Oettel M, Raitakari O, Saad F, Poellaenen PThe polymorphic androgen receptor gene CAG repeat, pituitary-testicular function and andropausal symptoms in ageing menInt J Androl 26: 187-194, 2003

20. A. Yassin, F. Saad, H.E. DiedeCombination therapy for erectile dysfunction with testosterone & tadalafil in hypogonadal patients who failed to respond to tadalafil aloneArab J Urol 1(4): 10-12, 2003

21. F. Saad, K. HeinemannAttitudes toward male fertility control. European results of a multinational survey37. Jahrestagung Physiologie und Pathologie der Fortpflanzung und 29. Veterinär- Humanmedizinische Gemeinschaftstagung February 19 and 20, Munich, Germany (Abstract)

22. C. Moore, D. Huebler, L.A.J. Heinemann, F. SaadThe AMS scale as androgen treatment outcome measureAging Male 7(1): 80, 2004 (Abstract)

23. C. Moore, D. Huebler, T. Zimmermann, L.A.J. Heinemann, F. Saad, D.M. ThaiThe Aging Males‘ Symptoms Scale (AMS) as outcome measure for treatment of androgen deficiencyEur Urol 46: 80-87, 2004

24. V. Bueber, R. Preuss, M. Witte, O. Gerke, M. Grote, F. SaadClinical and pharmacokinetic effects of testosterone undecanoate long-term treatment in hypogonadal men29th Annual Meeting of the American Society of AndrologyJ Androl Suppl., 24, 2004 (Abstract)

25. V.J. Bueber, O. Gerke, M. Grote, R.A. Preuss, F. Saad, M.F. WitteTreatment of hypogonadal men with long-acting testosterone undecanoate (TU): Clinical and pharmacokinetic results after intramuscular application of 1000 mg TU every three months up to 120 weeks86th Annual Meeting of the Endocrine Society, New Orleans, June 16-19, 2004 (Abstract)

26. F. Saad, S. White, K. HeinemannAttitudes toward hormonal male fertility control: USA results of a multinational survey86th Annual Meeting of the Endocrine Society, New Orleans, June 16-19, 2004 (Abstract)

27. L.A.J. Heinemann, F. Saad, K. Heinemann, D.M. ThaiCan results of the Aging Males‘ Symptoms (AMS) scale predict those of screening scales for androgen deficiency?

The Aging Male 7: 211-218, 2004

28. F. Saad, K. HeinemannAttitudes toward male fertility control. Results of a multinational surveyAndrologia, 36 (4): 159, 2004 (Abstract)

29. F. SaadDHEA in male and female sexual functionJ Sex Med 1(1): 14 (2004)

30. K. Heinemann, F. Saad, M. Wiesemes, S. White, L. HeinemannAttitudes toward male fertility control: results of a multinational survey in four continentsHuman Rep 20(2): 549-556, 2005

31. K. Heinemann, F. Saad, M. Wiesemes, L.A.J. HeinemannExpectations toward a novel male fertility control method and potential user types: results of a multinational surveyJ Androl 26(2): 155-162, 2005

32. L.A.J. Heinemann, P. Potthoff, K. Heinemann, A. Pauls, C.J. Ahlers, F. SaadScale for quality of sexual function (QSF) as an outcome measure for both genders?J Sex Med 2: 82-95, 2005

33. F. SaadThe role of testosterone in the Metabolic SyndromeEur J Clin Invest 35, Suppl. 2: 62, 2005 (Abstract)

34. M.C. Meriggiola, A. Costantino, F. Saad, L. D’Emisio, A.M. Morselli Labate, A. Bertaccini, W.J. Bremner, I. Rudolph, M. Ernst, B. Kirsch, G. Martorana, G. PelusiNorethisterone enanthate plus testosterone undecanoate for male contraception: Effects of various injection intervals on spermatogenesis, reproductive hormones, testis, and prostateJ Clin Endocrinol Metab 90(4): 2005-2014 (2005)

35. F. Saad, K. HeinemannA multinational survey on acceptability of male fertility control87th Annual Meeting of the Endocrine Society, San Diego, June 4-7, 2005 (Abstract)

36. M. Zitzmann, S. v. Eckardstein, F. Saad, E. NieschlagLong-term experience with injections of testosterone undecanoate for substitution therapy in hypogonadal men87th Annual Meeting of the Endocrine Society, San Diego, June 4-7, 2005 (Abstract)

37. F. Saad, A. RoemmlerDoes DHEA have a place in the treatment of the aging male?Int J Androl 28 (Suppl. 1): 49 (2005) (Abstract)

38. A.A. Yassin, F. SaadComparing the three PDE-5 inhibitors in the same populationInt J Androl 28 (Suppl. 1): 51 (2005) (Abstract)

39. A.A. Yassin, F. SaadChanges in penile cavernosography and venous leakage under testosterone therapy with Nebido in hypogonadal patients with erectile dysfunction: a case reportInt J Androl 28 (Suppl. 1): 53 (2005) (Abstract)

40. F. SaadThe metabolic syndrome: is testosterone deficiency a contributing factor? (A review of the current literature)Int J Androl 28 (Suppl. 1): 62 (2005) (Abstract)

41. A.A. Yassin, F. SaadModulation of erectile function with long-acting testosterone injection (Nebido) 1000 mg i.m. in hypogonadal patientsInt J Androl 28 (Suppl. 1): 63 (2005) (Abstract)

42. A.A. Yassin, F. SaadDoes long-acting testosterone injection (Nebido) have an impact on DHT?Int J Androl 28 (Suppl. 1): 63 (2005) (Abstract)

43. B. Lunenfeld, F. Saad, C.E. HoeslISA, ISSAM and EAU recommendations for the investigation, treatment and monitoring of llate-onset hypogonadism in males: Scientific background and rationaleThe Aging Male 8(2): 59-74 (2005)

44. Kratzik C, Heinemann LAJ, Saad F, Minh Thai D, Ruecklinger EComposite screener fro androgen deficiency related to the Aging Males’ Symptoms scaleAging amle 8(3/4): 157-161 (2005)

45. M. Zitzmann, S. v. Eckardstein, F. Saad, E. NieschlagExperiência a longo prazo com injeções de undecanoato de testosterona para terapia de reposiçao em homens hipogonádicosEndocrinologia & Metabologia 49(3) (Suplemento 2): S401-S402, 2005 (Abstract)

46. F. Saad, C.E. Hoesl, M. Oettel, J.-D. Fauteck, A. RömmlerDehydroepiandrosterone Treatment in the Aging Male – What Should the Urologist Know?Eur Urol 48: 724-733 (2005)

47. C.E. Hoesl, F. Saad, M. Pöppel, J.E. AltweinReversible, Non-Barrier Male Contraception: Status and ProspectsEur Urol 48: 712-723 (2005)

48. F. SaadTratamento da disfunção erétil: Uma reavaliação da testosteronaEssencial 2(10): 23-25 (2005)

49. Louis J.G. Gooren, F. Saad

Recent insights into androgen action on the anatomical and physiological substrate of penile erectionAsian J Androl 8(1): 1-7 (2006)

50. F. SaadTestosterone deficiency, erectile dysfunction, and the metabolic syndrome – how does it all fit together? (A review of the current literature)J Sex Med 3 (Suppl. 1): 55 (2006) (Abstract)

51. Yassin A, Saad F.Restoring of veno-occlusion in patients with metabolic syndrome/hypogonadism, penile venous leakage and ED by long-acting testosterone therapy – case reportJ Sex Med 3 (Suppl. 1): 66 (2006) (Abstract)

52. Yassin A, Saad F.Treatment of erectile function with long-acting testosterone injection i.m. in hypogonadal patientsJ Sex Med 3 (Suppl. 1): 67 (2006) (Abstract)

53. Yassin A, Saad F.Does long-acting testosterone injection have an impact on DHT?J Sex Med 3 (Suppl. 1): 67-68 (2006) (Abstract)

54. Zitzmann M, Saad F., Nieschlag ELongterm experience of more than 7 years with a novel formulation of testosterone undecanoate (Nebido) in substitution therapy of hypogonadal menJ Sex Med 3 (Suppl. 1): 68 (2006) (Abstract)

55. Zitzmann M, von Eckardstein S, Saad F., Nieschlag ELong-term experience with injections of testosterone undecanoate for substitution therapy in hypogonadal menJ Sex Med 3 (Suppl. 1): 69 (2006) (Abstract)

56. A. Yassin, F. Saad, C.E. Hoesl, A.M. Traish, M. Hammadeh, R. ShabsighAlpha-adrenoceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS – implications for clinical practiceAndrologia 38: 1-12 (2006)

57. A.A. Yassin, F. SaadDramatic improvement of penile venous leakage upon testosterone administration. A case report and review of literatureAndrologia 38: 34-37 (2006)

58. A.A. Yassin, F. SaadLong-acting testosterone ester injection as a second line therapy in hypogonadal patients with erectile dysfunctionThe Aging Male 9(1): 6 (2006) (Abstract)

59. A.A. Yassin, F. SaadLong-acting testosterone ester injection does not alter the dihydrotestosterone levelThe Aging Male 9(1): 23 (2006) (Abstract)

60. A.A. Yassin, F. SaadRestoring of veno-occlusion in patients with metabolic syndrome/hypogonadism, penile venous leakage and ED by long-acting testosterone injectionThe Aging Male 9(1): 24 (2006) (Abstract)

61. A.A. Yassin, F. Saad, H.E. DiedeTestosterone and erectile function in hypogonadal men unresponsive to tadalafil: results from an open-label uncontrolled studyAndrologia 38: 61-68 (2006)

62. M. Zitzmann, F. Saad, E. NieschlagLongterm experience of more than 8 years with a novel formulation of testosterone undecanoate (Nebido) in substitution therapy of hypogonadal menEndocrine Abstracts, 8th European Congress of Endocrinology, 11: P178 (2006) (Abstract)

63. A. Yassin, F. Saad, A. TraishTestosterone undecanoate restores erectile function in a subset of patients with venous leakage: a series of case reportsJ Sex Med 3(4): 727-735 (2006)

64. Yassin AA, Saad F, Guillaume A, Heinemann K, Haider AEffects of androgen deprivation on glycemic control and on biochemical cardiovascular risk factors in men with diabetesJ Urol 175 (4) Suppl.: 385 (Abstract 1196)

65. Behre H, J Elliesen, W Kuhnz, F Saad, Harnett MTestosterone undecanoate, a long-acting, 3-month depot testosterone replacement therapy88th Annual Meeting of the Endocrine Society, Boston, June 24-27, 2006 (Abstract)

66. M Zitzmann, F Saad, E NieschlagLongterm experience of up to 8.5 years with a long-acting formulation of testosterone undecanoate in substitution therapy of hypogonadal men88th Annual Meeting of the Endocrine Society, Boston, June 24-27, 2006 (Abstract)

67. M Zitzmann, F SaadInfluence of a long-acting testosterone preparation (intramuscular injections of testosterone undecanoate) on hemostatic and inflammatory markers in healthy men 88th Annual Meeting of the Endocrine Society, Boston, June 24-27, 2006 (Abstract)

68. F Saad, A Traish, A Yassin, S Kalinchenko, R ShabsighThe role of testosterone in the metabolic syndrome and erectile dysfunction2nd Continuing Medical Education Symposium on Men’s Health, Reproduction, Sex and Aging, School of Medicine Hang Tuah University, Surabaya, Indonesia, August 10, 2006 (Abstract)

69. A Yassin and F SaadInnovation of new testosterone therapy for treatment of male hypogonadism

2nd Congress of the Indonesian Association of Sexology and 1st INA International Symposium on Sexual Medicine, Surabaya, Indonesia, August 11-13, 2006 (Abstract)

70. F Saad, D Huebler, A Yassin, M Zitzmann, F Jockenhoevel, M Oettel Hormone deficiency in aging men: An update on testosterone treatment2nd Congress of the Indonesian Association of Sexology and 1st INA International Symposium on Sexual Medicine, Surabaya, Indonesia, August 11-13, 2006 (Abstract)

71. A Morales and F SaadDehydroepiandrosterone (DHEA) in aging male: The mystery and the truth8th Asian Congress of Urology, Nusa Dua, Bali, Indonesia, August 22-26, 2006 (Abstract)

72. Yassin AA, Saad F, Guillaume A, Heinemann K, Haider ATreatment of prostate cancer with androgen deprivation impairs glucose and lipid metabolism in diabeticsJ Sex Med 3 (Suppl. 5): 402 (2006)

73. Yassin AA, Haider A, Saad FHaematospermia: Usually medically innocent but anxiety provoking for the patientJ Sex Med 3 (Suppl. 5): 396 (2006)

74. Yassin AA, Haider A, Saad FFavorable effects of early “penile rehabilitation” following nerve sparing radical prostatectomyJ Sex Med 3 (Suppl. 5): 407 (2006)

75. Yassin AA and Saad FParenteral administration of long-acting testosterone undecanoate does not generate supraphysiological dihydrotestosterone levelsJ Sex Med 3 (Suppl. 5): 425 (2006)

76. Saad F, Zitzmann M, Nieschlag EExperience and safety of 44 treatment-years with a long-acting formulation of testosterone undecanoate (Nebido®) in the treatment of male hypogonadismJ Sex Med 3 (Suppl. 5): 430 (2006)

77. Saad F, Schwerdt S, Yassin A Testosterone treatment of erectile dysfunction: A forgotten but effective first line treatment?J Sex Med 3 (Suppl. 5): 443-444 (2006)

78. Saad F, Yassin AA Testosterone treatment has a restorative effect on venous leakage of the corpus cavernosumJ Sex Med 3 (Suppl. 5): 444 (2006)

79. F Saad, Schwerdt S, Yassin AA

Hypogonadal patients with erectile dysfunction should first receive adequate testosterone treatmentJ Sex Med 3 (Suppl. 5): 444-445 (2006)

80. Saad F, Yassin AA, Shabsigh R Erectile dysfunction, the metabolic syndrome, and testosterone deficiency – is there a link?J Sex Med 3 (Suppl. 5): 448 (2006)

81. A Yassin, F SaadTreatment of sexual dysfunction of hypogonadal patients with long-acting testosterone undecanoate (Nebido®)World J Urol 24: 639-644 (2006)

82. A Yassin, D Huebler, F SaadLong-acting testosterone undecanoate for parenteral testosterone therapyTherapy 3(6): 709-721 (2006)

83. F Saad, A Traish, A Yassin, S Kalinchenko, R ShabsighThe metabolic syndrome and erectile dysfunction: Testosterone may be a common denominatorJ Sex Med 4 (Suppl. 1): 83-84 (2007)

84. A Yassin and F SaadMany elderly hypogonadal men with erectile dysfunction respond favourably to treatment with testosterone onlyJ Sex Med 4 (Suppl. 1): 92 (2007)

85. A Yassin, F Saad, A TraishTestosterone may restore penile venous leakage in patients with hypogonadism and erectile dysfunctionJ Sex Med 4 (Suppl. 1): 81 (2007)

86. A Yassin, A Haider, F SaadComparison of the efficacy / drawbacks of two modalities of testosterone treatment: Transdermal testosterone gel and injectable long-acting testosterone undecanoateJ Sex Med 4 (Suppl. 1): 84 (2007)

87. A Haider, A Yassin, F Saad, R ShabsighAndrogen deprivation of men with prostate cancer induces features of the metabolic syndromeJ Sex Med 4 (Suppl. 1): 87-88 (2007)

88. F Saad and K HeinemannWhat do men think about male fertility control?J Sex Med 4 (Suppl. 1): 82 (2007)

89. F Saad, M Zitzmann, E NieschlagSafety and efficacy of the new long acting injectable testosterone preparation testosterone undecanoateJ Sex Med 4 (Suppl. 1): 82 (2007)

90. AA Yassin, C Moore, F SaadVerbesserung der erektilen Funktion bei Männern mit altersassoziiertem Hypogonadismus unter alleiniger TestosteronbehandlungBlickpunkt DER MANN, 4(3): 46-49 (2006)

91. Yassin A, Saad FPlasma levels of dihydrotestosterone remain in the normal range in men treated with long-acting parenteral testosterone undecanoateJ Sex Med, Book of Abstracts ESSM 2006: 43 (2006)

92. Saad F, Yassin A, Shabsigh R, Traish A, Kalinchenko S, Eardley ITestosterone is the therapeutical bridge between metabolic syndrome and erectile dysfunctionJ Sex Med, Book of Abstracts ESSM 2006: 68-69 (2006)

93. Yassin A, Haider A, Saad FTwo modern modes of testosterone treatment compared: Transdermal testosterone gel and injectable long-acting testosterone undecanoateJ Sex Med, Book of Abstracts ESSM 2006: 69 (2006)

94. Farid Saad, Kamischke A, Yassin A, Zitzmann M, Schubert M, Jockenhövel F, Behre HM, Gooren L, Nieschlag EMore than eight years’ hands-on experience with the novel long-acting parenteral testosterone undecanoateAsian J Androl 9(3): 291-297 (2007)

95. Farid Saad, Anca S. Grahl, Antonio Aversa, Aksam A. Yassin, Ates Kadioglu, Ignacio Moncada and Ian EardleyEffects of testosterone on erectile function: implications for the therapy of erectile dysfunctionBJU Int 99(5): 988-992 (2007)

96. Aksam A. Yassin, Doris Huebler & Farid SaadLong-acting testosterone undecanoate for parenteral testosterone therapyTherapy 3(6): xxx-xxx (2007)

97. Heufelder A, Saad F, Gooren LAdditional therapeutic action of testosterone to the favourable effects of exercise and diet in diabetes type 2J Urol 177(4): 228 (2007)

98. Yassin AA and Saad FErectile dysfunction, metabolic syndrome, hypogonadism are intertwinedJ Urol 177(4): 288 (2007)

99. Armin Heufelder, Louis J. Gooren, Farid SaadTestosterone replacement enhances the favorable effects of exercise and dietary modification in hypogonadal men with type 2 diabetes mellitus89th Annual Meeting of the Endocrine Society, Toronto, June 02-05, 2007 (Abstract book: 151)

100. Michael Zitzmann, Farid Saad, Eberhard NieschlagNew models to improve safety of testosterone substitution by pharmacogenetics and obesity status: experience of 118 treatment-years with a long-acting formulation of testosterone undecanoate89th Annual Meeting of the Endocrine Society, Toronto, June 02-05, 2007 (Abstract book: 440-441)

101. Louis J. Gooren, Farid Saad, Ahmad Haider, Aksam YassinHypogonadal men have a wide range of dihydrotestosterone levels. High levels fall upon testosterone administration.89th Annual Meeting of the Endocrine Society, Toronto, June 02-05, 2007 (Abstract book: 442)

102. Farid Saad, Louis J. Gooren, Ahmad Haider, Aksam YassinComparison of the effects of testosterone gel with parenteral testosterone undecanoate on features of the metabolic syndrome89th Annual Meeting of the Endocrine Society, Toronto, June 02-05, 2007 (Abstract book: 605)

103. Farid Saad, Louis J. Gooren, Ahmad Haider, Aksam YassinEffects of testosterone administration on variables of the metabolic syndrome89th Annual Meeting of the Endocrine Society, Toronto, June 02-05, 2007 (Abstract book: 605)

104. Maria Cristina Meriggiola, Francesca Armillotta, Antonietta Costantino, Silvia Cerpolini, Laura D’Emidio, Marta Berra, Anna Myriam Perrone, Farid Saad, Andreas Mattern, Giuseppi PelusiHormonal and metabolic effects of testosterone undecanoate (TU) administered alone or in combination with letrozole or dutasteride in female to male (FtM) transsexuals89th Annual Meeting of the Endocrine Society, Toronto, June 02-05, 2007 (Abstract book: 606)

105. LJ Gooren, HM Behre, F Saad, A Frank, S SchwerdtDiagnosing and treating testosterone deficiency in different parts of the world. Results from global market researchAging Male 10(4): 173-181 (2007)

106. F Saad, LJ Gooren, A Haider, A YassinAn exploratory study of the effects of 12 months administration of the novel long-acting testosterone undecanoate on measures of sexual function and the metabolic syndromeArch Androl 53(6): 353-357 (2007)

107. LJ Gooren, F Saad, A Haider, A Yassin, S SakhriA decline of plasma 5α-dihydrotestosterone (DHT) levels upon testosterone administration to elderly men with subnormal plasma testosterone and high DHT levelsAndrologia (2008)

108. F Saad, LJ Gooren, A Haider, A YassinA dose response study of testosterone on sexual dysfunction and on features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoateJ Androl 29(1): 102-105 (2008)

109. F Saad, LJ Gooren, A Haider, A YassinEffects of testosterone gel followed by parenteral testosterone undecanoate on sexual dysfunction and on features of the metabolic syndromeAndrologia 40(1): 102-105 (2008)

110. A Yassin and F SaadPlasma levels of dihydrotestosterone remain in the normal range in men treated with long-acting parenteral testosterone undecanoateAndrologia 39(4): 181-184 (2007)

111. S Kalinchenko and F SaadThe efficacy of testosterone administration on erectile dysfunction in elderly men with testosterone deficiency1st Meeting of the European Society for the Study of the Aging Male (ESSAM), Warsaw, Poland, June 14-16, 2007 (Abstract book: 45)

112. EN Arinina, YA TishovaS, F Saad, SY KalinchenkoEffect of testosterone treatment on inflammatory markers in men with late-onset hypogonadism (LOH) and the metabolic syndrome (MS)1st Meeting of the European Society for the Study of the Aging Male (ESSAM), Warsaw, Poland, June 14-16, 2007 (Abstract book: 83)

113. A Haider, A Yassin, F Saad, R ShabsighEffects of androgen deprivation on glycemic control and on cardiovascular biochemical risk factors in men with advanced prostate cancer with diabetesAging Male 10(4): 189-196 (2007)

114. F Saad, LJ Gooren, A HeufelderTestosterone enhances the effects of lifestyle modifications in hypogonadal men with newly diagnosed type 2 diabetesJ Men’s Health Gender 4(3): 365 (2007)

115. F Saad, LJ Gooren, A Haider, A YassinTestosterone treatment with testosterone undecanoate injections has beneficial effects on variables of the metabolic syndrome in elderly hypogonadal menJ Men’s Health Gender 4(3): 365 (2007)

116. YA Tishova, GZ Mskhalaya, F Saad, SY KalinchenkoEffect of testosterone treatment on inflammatory markers in men with late-onset hypogonadism (LOH) and metabolic syndrome (MS)J Men’s Health Gender 4(3): 366 (2007)

117. A Yassin and F SaadThe associated link between erectile dysfunction, metabolic syndrome, and hypogonadism

J Men’s Health Gender 4(3): 371-372 (2007)

118. A Yassin and F SaadTestosterone and obesity: generic aspects and specific experienceJ Men’s Health Gender 4(3): 372-373 (2007)

119. F SaadWhat is the future of treating the testosterone deficiency syndrome?APSSM Abstract Book: 112 (2007)

120. F Saad, L Gooren, A Haider, A YassinDose effects of testosterone on features of the metabolic syndrome: parenteral testosterone undecanoate compared with testosterone gelAPSSM Abstract Book: 87 (2007)

121. F Saad, A Heufelder, LJ GoorenThe favourable effects of exercise and dietary modification in hypogonadal men with type 2 diabetes mellitus are enhanced by testosterone administrationAPSSM Abstract Book: 121 (2007)

122. F Saad, S Freude, D Hübler, M Oettel, M Schubert, LJ Gooren, F JockenhövelEfficacy and safety of the long-acting parenteral testosterone undecanoate: a four-year follow-upAPSSM Abstract Book: 121 (2007)

123. M Zitzmann, F Saad, E NieschlagPharmacogenetics and body mass modulate safety of testosterone substitution: experience of 118 treatment-years with a long-acting formulation of testosterone undecanoateAPSSM Abstract Book: 120 (2007)

124. F Saad, LJ Gooren, A Haider, A YassinHigh levels of dihydrotestosterone in hypogonadal men decline upon normalization of testosterone levelsAPSSM Abstract Book: 120 (2007)

125. A Yassin and F SaadVeno-occlusive impotence and erectile dysfunction: treatment and outcomes(invited textbook chapter)

126. A Yassin and F SaadEvident effect of testosterone therapy only in hypogonadal men with erectile dysfunctionDer Urologe 46(Suppl. 1): 92 (2007)

127. A Yassin, F Saad, A HaiderEffects of testosterone administration on variables of the metabolic syndrome with two different testosterone preparationsDer Urologe 46(Suppl. 1): 75 (2007)

128. A Yassin and F Saad

The link between erectile dysfunction, metabolic syndrome and testosterone deficiency: outcome of data analyses of 771 ED patientsJ Sex Med 5(Suppl. 2): 112 (2007)

129. A Yassin, A Haider, A Shamsodini, F Saad, S AlkadiDoes testicular volume alter under testosterone therapy?J Sex Med 5(Suppl. 2): 128 (2007)

130. A Shamsodini, A Yassin, F Saad, R Alzubaidi, S Alkadi, A Al AnsariRigiscan monitoring of nocturnal tumescence in patients with low testosterone level treated with testosterone undecanoateJ Sex Med 5(Suppl. 2): 90 (2007)

131. F Saad, A Yassin, A HaiderAssociation between androgen deprivation therapy and deterioration of glycemic control and cardiovascular risk factors in men with type 2 diabetes mellitusSLAMS Abstract Book: 15 (2007)

132. F Saad, L Gooren, A Haider, A Yassin12 months administration of a long-acting formulation of testosterone undecanoate (Nebido) improves measures of sexual dysfunction and the metabolic syndromeSLAMS Abstract Book: 26 (2007)

133. F Saad, L Gooren, A Haider, A YassinLong-acting testosterone undecanoate is more efficient than testosterone gel in improving features of the metabolic syndrome in hypogonadal menSLAMS Abstract Book: 26 (2007)

134. F Saad, L Gooren, A Haider, A Yassin15 months of treatment with long-acting testosterone undecanoate (Nebido) improves features of the metabolic syndromeSLAMS Abstract Book: 42 (2007)

135. S Freude, D Huebler, M Oettel, M Schubert, L Gooren, F Jockenhoevel, F SaadEfficacy and safety of long-acting testosterone undecanoate over 4 yearsSLAMS Abstract Book: 43 (2007)

136. L Gooren, F Saad, A Haider, A YassinHigh plasma levels of dihydrotestosterone decline in hypogonadal men following testosterone substitutionSLAMS Abstract Book: 41 (2007)

137. T Minnemann, F Saad, M Schubert, D Huebler, D Rouskova, I Gouni-Berthold, C Schumann, A Christoph, M Oettel, M Ernst, U Mellinger, W Krone, L Gooren, F JockenhoevelComparison of the safety and efficacy of a novel long-acting formulation of testosterone undecanoate with testosterone enanthate in hypogonadal menSLAMS Abstract Book: 27 (2007)

138. Y Tishova, G Mskhalaya, F Saad, Y Kalinchenko

Testosterone treatment with long-acting testosterone undecanoate in men with late-onset hypogonadism and the metabolic syndrome reduced serum levels of interleukin-6, tumor necrosis factor alpha and C-reactive proteinSLAMS Abstract Book: 41 (2007)

139. M Zitzmann, F Saad, E NieschlagThe safety and efficacy of a long-acting formulation of testosterone undecanoate is modulated by body mass and pharmacogenetic variables: Experience of 118 treatment-years of testosterone substitutionSLAMS Abstract Book: 27 (2007)

140. K Heinemann, R Anderson, D Baird, F Saad, R Shabsigh, LAJ HeinemannAttitudes toward male fertility control – results of two multinational surveys on five continentsManuscript submitted

141. A Yassin and F SaadThe link between erectile dysfunction, metabolic syndrome and testosterone deficiency: outcome of data analyses of 771 ED patientsAGSSM Abstract Book: 29-30 (2007)

142. A Shamsodini, A Yassin, F Saad, R Alzubaidi, S Alkadi, A Al AnsariRigiScan monitoring of nocturnal tumescence in patients with low testosterone level treated with testosterone undecanoateAGSSM Abstract Book: 34-35 (2007)

143. A Yassin, A Haider, A Shamsodini, F Saad, S AlkadiThe testicular volume alters under testosterone therapyAGSSM Abstract Book: 55-56 (2007)

144. A Heufelder, F Saad, M Bunck, L Gooren52-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in hypogonadal men with newly diagnosed type 2 diabetesManuscript submitted (2008)

145. F Saad, L Gooren, A Haider, A YassinSignificance of plasma levels for effects of testosterone on the metabolic syndromeAging Male 11(1): 39 (2008)

146. F Saad, A Heufelder, L GoorenTestosterone administration in addition to exercise and diet enhance therapeutic effects in men with type 2 diabetes with subnormal testosteroneAging Male 11(1): 11 (2008)

147. YA Tishova, GZ Mskhalaya, F Saad, SY KalinchenkoEffect of testosterone treatment on cardiovascular risk factors and variables of the metabolic syndrome (MS) in hypogonadal menAging Male 11(1): 19-20 (2008)

148. A Yassin, A Haider, A Shamsodini, F Saad

The testicular volume alters under testosterone therapyAging Male 11(1): 18 (2008)

149. A Shamsodini, F Saad, A Yassin, R Alzubaidi, A Al AnsariRigiScan monitoring of nocturnal tumescence in patients with low testosterone level treated with testosterone undecanoateAging Male 11(1): 40-41 (2008)

150. A Yassin and F SaadThe link between erectile dysfunction, metabolic syndrome and testosterone deficiency: outcome of data analysis of 771 ED patientsAging Male 11(1): 29 (2008)

151. SY Kalinchenko, EL Vishnevskiy, AN Koval, GJ Mskhalaya, F SaadBeneficial effects of testosterone administration on symptoms of the lower urinary tract in men with late onset hypogonadism: a pilot studyAging Male accepted (2008)

152. AM Traish, A Guay, R Feeley, F SaadThe dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunctionJ Androl submitted (2008)

153. A Yassin and F SaadThe link between erectile dysfunction, metabolic syndrome and testosterone deficiency: outcome of data analysis of 771 ED patientsEuropean Urology Supplements 7(3): 296 (2008)

154. F Saad, A Heufelder, L GoorenNormalization of testosterone levels enhances the favourable effects of exercise and diet in men with diabetes type 2 with subnormal testosteroneJ Androl (Suppl.): 54 (2008)

155. F Saad, A Haider, A Yassin, L GoorenWith regard to testosterone (patho)physiology men are not created equalJ Androl (Suppl.): 54 (2008)

156. M Zitzmann, E Vorona, M Wenk, F Saad, E NieschlagTestosterone administration decreases carotid intima media thickness as indicator of vascular damage in middle-aged overweight menJ Androl (Suppl.): 54-55 (2008)

157. MC Meriggiola, F Armilotta, A Costantino, P Altieri, AM Perrone, F Saad, T Ghi, C Pelusi, G PelusiEffects of testosterone undecanoate (TU) administered alone or in combination with letrozole or dutasteride in female-to-male (FtM) transsexualsJ Sex Med (2008)

158. A Yassin and F SaadDer Link zwischen erektiler Dysfunktion und metabolischem Syndrom – Möglichkeiten der BehandlungBlickpunkt Der Mann, 6(1): 10-14 (2008)

159. F Saad and A HaiderC-reactive protein levels and Aging Male Symptoms (AMS) in hypogonadal men treated with testosterone supplementationSAUA 2008

160. F Saad and A HaiderTestosterone administration to elderly hypogonadal men improves the metabolic syndrome and liver steatosis SAUA 2008

161. F Saad and A HaiderAge and baseline testosterone value do not predict the beneficial effect of normalization of testosterone on the metabolic syndromeSAUA 2008

162. F Saad and A HaiderConcurrent improvement of the metabolic syndrome and lower urinary tract symptoms upon normalization of plasma testosterone levels in hypogonadal elderly menSAUA 2008

163. F Saad and A HaiderSafety aspects of administration of parenteral testosterone undecanoate to elderly men SAUA 2008

164. A Traish and F SaadIs There a Place for Androgen Therapy in Sexual Medicine? Current Approaches and Future DevelopmentsInvited book chapter (submitted)

165. A Traish, A Guay, F SaadThe dark side of testosterone deficiency: II. Type 2 diabetes and insulin resistanceJ Androl (submitted)

166. A Yassin, A El-Sakka, F SaadTestosterone and erectile dysfunctionIn: Jones H, Testosterone Deficiency in Men, Oxford University Press, Oxford, UK 2008: 97-105

167. A Haider, L Gooren, P Padungtod, F SaadAge and baseline testosterone value do not predict the beneficial effect of normalization of testosterone on the metabolic syndromeJ Androl (submitted)

168. A Haider, L Gooren, P Padungtod, F SaadSafety aspects of administration of parenteral testosterone undecanoate to elderly menAsian J Androl (submitted)

169. EJ Giltay, A Haider, F Saad, L GoorenC-reactive protein levels and aging male symptoms (AMS) in hypogonadal men treated with testosterone supplementationAndrologia (submitted)

170. A Haider, L Gooren, P Padungtod, F SaadImprovement of the metabolic syndrome and of non-alcoholic liver steatosis upon treatment of hypogonadal elderly men with testosterone undecanoateTo be submitted

171. F SaadThe role of testosterone in the metabolic syndrome Journal of Steroid Biochemistry & Molecular Biology (accepted)

172. F SaadC-reactive protein levels and aging male symptoms in hypogonadal men treated with testosterone supplementationJournal of Steroid Biochemistry & Molecular Biology (accepted)

173. F SaadAge and baseline testosterone value do not predict the beneficial effect of normalization of testosterone on the metabolic syndromeJournal of Steroid Biochemistry & Molecular Biology (accepted)

174. F SaadComparison of long-acting testosterone undecanoate formulation versus testosterone enanthate on sexual function and mood in hypogonadal menJournal of Steroid Biochemistry & Molecular Biology (accepted)

175. A Yassin, F Saad, A Haider, O AsaadNo higher incidence of prostate cancer in hypogonadal patients treated with exogenous testosteroneDGU 2008 (submitted)

180. A Al Ansari, A Yassin, F Saad, S Alkadi, A ShamsodiniRigiScan monitoring of erectile findings and nocturnal tumescence in testosterone-deficient patients treated with testosterone undecanoate injectionsDGU 2008 (submitted)

181. A Yassin, A Haider, F Saad Is there an alteration in testicular volume under exogenous testosterone treatment?DGU 2008 (submitted)

182. A Yassin, F Saad, R ShabsighTestosterone is the bridge between metabolic syndrome and erectile dysfunctionDGA 2008 (submitted)

183. A Yassin and F SaadProstate cancer and testosterone therapy – is thee an expectation of paradigm shift?DGA 2008 (submitted)

184. A Yassin, A Haider, A Shamsodini, F SaadExogenous testosterone therapy and testicular volume – is there an alteration?DGA 2008 (submitted)

185. A Shamsodini, A Yassin, F Saad, R Alzubaidi, S Alkadi, A Al AnsariRigiScan monitoring of nocturnal tumescence in patients with low testosterone level treated with testosterone undecanoateDGA 2008 (submitted)

186. A Yassin and F SaadCo-morbidities in erectile dysfunction patients and with attention to those with testosterone deficiencyDGA 2008 (submitted)

187. A Yassin, F Saad, A HaiderTestosterone treatment in hypogonadal patients does not cause higher incidence of prostate cancerDGA 2008 (submitted)

188. A Heufelder, L Gooren, M Bunck, F SaadTestosteronbehandlung erhöht die positive Effekte von Ernährungs- und Bewegungstherapie auf Entzündungs- und Blutgerinnungsmarker im Zusammenhang mit Typ 2-Diabetes bei hypogonadalen MännernDGA 2008 (submitted)

189. A Heufelder, L Gooren, M Bunck, F SaadErnährungs- und Bewegungstherapie in Kombination mit Testosteronbehandlung revidiert das metabolische Syndrom und verbessert glyzämische Kontrolle bei hypogonadalen Männern mit neu diagnostiziertem Typ 2-DiabetesDGA 2008 (submitted)

190. F Saad, L Gooren, A HaiderAlter und Testosteron-Ausgangswerte erlauben keinen Rückschluß auf die positive Wirkung der Normalisierung von Testosteron auf Komponenten des metabolischen SyndromsDGA 2008 (submitted)

191. F Saad, L Gooren, A Haider

Sicherheit der Testosteronbehandlung beim älteren MannDGA 2008 (submitted)

192. F Saad, A Haider, M Bunck, L GoorenVerbesserung der Leberfunktion parallel zu Verbesserungen der Parameter des metabolischen Syndroms unter TestosteronbehandlungDGA 2008 (submitted)

193. F Saad, L Gooren, A HaiderTestosteronbehandlung bei älteren hypogonadalen Männern verbessert Symptome des unteren Harntrakts (Lower Urinary Tract Symtoms, LUTS) parallel zu Verbesserungen der Komponenten des metabolischen SyndromsDGA 2008 (submitted)

194. F Saad, A Haider, M Bunck, L GoorenPositive Effekte der Normalisierung von Testosteronwerten bei Männern mit dem metabolischen SyndromDGA 2008 (submitted)

195. Y Tishova, F Saad, G Mskhalaya, S KalinchenkoTestosteronbehandlung bei Männern mit Late-Onset Hypogonadismus (LOH) und metabolischem Syndrom – vorläufige Ergebnisse einer randomisierten, Plazebo-kontrollierten DoppelblindstudieDGA 2008 (submitted)

196. Y Tishova, F Saad, G Mskhalaya, S KalinchenkoEffekt der Testosteronbehandlung auf Entzündungsfaktoren bei Männern mit Late-Onset Hypogonadismus (LOH) und metabolischem Syndrom – vorläufige Ergebnisse einer randomisierten, Plazebo-kontrollierten DoppelblindstudieDGA 2008 (submitted)

197. F Saad and A HaiderC-reactive protein levels and aging male symptoms in hypogonadal men treated with testosterone supplementationICE 2008 (submitted)

198. F SaadComparison of long-acting testosterone undecanoate formulation versus testosterone enanthate on sexual function and mood in hypogonadal menICE 2008 (submitted)

199. A Heufelder, L Gooren, M Bunck, F SaadTreatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in hypogonadal men with newly diagnosed type 2 diabetesICE 2008 (submitted)

200. F Saad and A HaiderTestosterone administration to elderly hypogonadal men improves the metabolic syndrome and liver steatosisICE 2008 (submitted)

201. F Saad and A HaiderAge and baseline testosterone value do not predict the beneficial effect of normalization of testosterone on the metabolic syndromeICE 2008 (submitted)

202. S Kalinchenko, Y Tishova, G Mskhalaya, J Orlov, F SaadErectile function, intima-media thickness and blood flow rate in arteries of the penis in men with arteriogenic erectile dysfunction after two months treatment with the PDE5-inhibitor VardenafilICE 2008 (submitted)

Oral Presentations

1. F SaadDer alternde Mann. Forschungsaktivitaeten bei Jenapharm5. Wissenschaftliche Tagung der Suedostdeutschen Gesellschaft fuer Urologie, Landshut, Germany, June 10,1999

2. F SaadHormontief des Mannes Aerzte-Fortbildung Jenapharm, Wiesbaden, Germany, September15,1999

3. F SaadHormontief des Mannes - TherapieansätzeAerzte-Fortbildung Jenapharm, Luebeck, Germany, September 22,1999

4. F SaadAndrogensubstitution in der andrologischen TherapieReproduktionsbiologisches Kolloquium der Hautklinik der Justus-Liebig-Universität Giessen Giessen, Germany, October 20,1999

5. F SaadDer alternde Mann. Forschung und Entwicklung bei JenapharmOesterreichische Akademie der Wissenschaften, Innsbruck, Austria, December 15,1999

6. M Oettel, B Allolio, W Arlt, T Graeser, D Huebler, V Patchev, F Saad, U Schumacher, BR Winkelmann Hormone replacement vs. hormone displacement in the aging male2nd World Congress on The Aging Male, Geneva, Switzerland, February 12, 2000

7. F SaadAging Male. Forschungsaktivitaeten bei JenapharmLigeko Fachtagung Kollagenstoffwechsel und Anti-Aging, Koblenz, Germany, May 27, 2000

8. F SaadCan DHEA serve as an oral androgen in hormonal male contraception?IVth Summit Meeting on Hormonal Male Contraception, Dozza, Italy, June 29, 2000

9. F SaadDas Klimakterium des MannesAerzte-Fortbildung Jenapharm, Wiesmoor, Germany, September 27, 2000

10. F SaadEstrogens for menSymposium on Male Reproductive Endocrinology, University of Jakarta, Jakarta, Indonesia, November 07, 2000

11. F SaadAndrogen substitution in the aging maleSymposium on Male Reproductive Endocrinology, University of Jakarta, Jakarta, Indonesia, November 07, 2000

12. F SaadThe aging male project – research and development at Jenapharm, Jena, Germany8th National Congress on Andrology and International Symposium on New Perspectives of Andrology in Human Reproduction, Padang, Indonesia, November 10, 2000

13. F SaadResearch and development in Male AgingSeminar Gluck Equine Research Center, University of Kentucky, Lexington, Kentucky, U.S.A., November 20, 2000

14. F SaadDHEA substitution in the aging male: Rationale and future perspectiveIndonesian Society of Andrology, Bali, Indonesia, July 21, 2002

15. F SaadDHEA in male and female sexual functionIndonesian Society of Sexology, Bali, Indonesia, July 22, 2002

16. F SaadAndrogens in male and female sexual functionScientific Symposium University of Manado, Manado, Indonesia, July 23, 2002

17. F SaadDehydroepiandrosterone (DHEA) substitution in the aging male: Where do we stand today?2nd Asian ISSAM Meeting on the Aging Male, Taipei, Taiwan, March 06-09, 2003

18. F SaadAktueller Stand der Fertilitätskontrolle beim Mann26. Internationale Fortbildungswoche, Thyon, Switzerland, March 19, 2003

19. F SaadAndrogen deficiency and late onset hypogonadismScientific Advisory Board Meeting, Dublin, Ireland, February 21, 2003

20. F SaadAndrogen deficiency and late onset hypogonadismScientific Advisory Board Meeting, Cork, Ireland, May 15, 2003

21. F SaadProspective / future developments in androgen therapy: Overview of hypogonadism researchScientific Symposium, London, UK, May 16, 2003

22. F SaadTestosterone and the metabolic syndrome11th Congress of the German-Syrian Society of Urology, Norderstedt, Germany, June 21, 2003

23. F SaadTestogel studies and new developments in androgen therapyScientific Symposium, Helsinki, Finland, September 01, 2003

24. F SaadTestosterone and the metabolic syndromeColloquium at University of Sheffield, Sheffield, UK, September 08, 2003

25. F SaadMale Fertility Control – Multinational Survey on Attitudes, Desires, and Acceptability of Male Fertility ControlVIIth Summit Meeting on Hormonal Male Contraception, Elmau, Germany, September 29, 2003

26. F SaadTestogel: Efficacy and safety of a new testosterone formulationScientific Symposium Schering Italy, Berlin, Germany, October 24, 2003

27. F SaadThe endless story of DHEA4th World Congress on the Aging Male, Prague, February 26-29, 2004

28. F Saad, P DroescherDHEA and Ageing – an Endless Story?Analytica, Munich, May 11, 2004

29. F SaadHormonal male fertility control12th Congress of the German-Syrian Society of Urology, Norderstedt, Germany, July 03, 2004

30. F SaadHormonelle Fertilitätskontrolle beim MannAerzte-Fortbildung Lueneburg, Germany, July 07, 2004

31. F SaadMultinational survey on attitudes, desires, and acceptability of male fertility control3rd European Congress of Andrology (ECA), Muenster, Germany, Sept, 13, 2004

32. F SaadRôle de la testostérone dans la function et dysfonction érectile1er Congrès International de la STRSI, Tunis, Tunisia, Sept. 17, 2004

33. F SaadLa testostérone et le syndrome métabolique1er Congrès International de la STRSI, Tunis, Tunisia, Sept. 17, 2004

34. DT Baird, RA Anderson, AF Glasier, K Heinemann, F SaadAcceptability and cultural attitudes towards male hormonal contraceptionCongress on The Future of Male Contraception, Seattle, USA, Sept. 30, 2004

35. F SaadDHEA in male and female sexual function11th World Congress of The International Society for Sexual and Impotence Research, Buenos Aires, Argentina, Oct. 13, 2004

36. F SaadA new long-acting injection of Testosterone Undecanoate (Nebido)Advisory Board Schering Austria Andrology Meeting, Vienna, Austria, Nov. 06, 2004

37. F SaadFertilitaetskontrolle beim Mann4. Symposium Themenreihe Gynäkologie und Geburtshilfe, Charité, Berlin, Germany, Nov. 13, 2004

38. F SaadThe Aging Male – An Invention or Reality?Demographic and Hormonal ChangesInternational Conference on Men’s Health & Male Aging, Gulf Medical College, Ajman, UAE, Dec. 23, 2004

39. F SaadMale Aging – Clinical Signs and Symptoms of Testosterone Deficiency in Body and MindInternational Conference on Men’s Health & Male Aging, Gulf Medical College, Ajman, UAE, Dec. 23, 2004

40. F SaadRisks and Side Effects of Testosterone TherapyInternational Conference on Men’s Health & Male Aging, Gulf Medical College, Ajman, UAE, Dec. 23, 2004

41. F SaadThe Aging Male – An Invention or Reality?Demographic and Hormonal ChangesInternational Symposium on Men’s Health & Male Aging, Hamad Medical Center, Doha, Qatar, Dec. 25, 2004

42. F SaadMale Aging – Clinical Signs and Symptoms of Testosterone Deficiency in Body and MindInternational Symposium on Men’s Health & Male Aging, Hamad Medical Center, Doha, Qatar, Dec. 25, 2004

43. F SaadRisks and Side Effects of Testosterone TherapyInternational Symposium on Men’s Health & Male Aging, Hamad Medical Center, Doha, Qatar, Dec. 25, 2004

44. F SaadThe Role of Testosterone in the Metabolic Syndrome3rd Meeting of the Asia Pacific Society for the Study of the Aging Male, Chiang Mai, Thailand, Jan 26, 2005

45. F SaadExperience with a Novel Long-term Depot Injection of Testosterone Undecanoate3rd Meeting of the Asia Pacific Society for the Study of the Aging Male, Chiang Mai, Thailand, Jan 27, 2005

46. F SaadDie Rolle von Testosteron in der Sexualitaet des alternden Mannes1. Fortbildungsveranstaltung der Akademie für Präventiv- und Anti-Aging-Medizin, Münster, Germany, Feb 19, 2005

47. F SaadClinical Experience with a New, Long-acting Injection of Testosterone Undecanoate4th International Conference of the Society for the Study of Androgen Deficiency, London, UK, Feb. 24 and 25, 2005

48. F SaadTestosterone and the Metabolic Syndrome4th International Conference of the Society for the Study of Androgen Deficiency, London, UK, Feb. 24 and 25, 2005

49. F SaadThe role of testosterone in the Metabolic Syndrome39th Annual Meeting of the European Society for Clinical Investigation, Athens, Greece, April 7, 2005

50. M Oettel, F SaadDHEAAnnual Meeting of the German Society for Anti-Aging Medicine, Munich, Germany, June 3, 2005

51. F SaadThe role of testosterone in the aging maleLecture at Korea University Hospital, Seoul, Korea, June 15, 2005

52. F SaadThe role of testosterone in male sexual function54th Pusan Urological Forum, Pusan, Korea, June 16, 2005

53. F SaadExperience with a novel, long-acting injection of testosterone undecanoateCME Symposium Hang Tuah University, Surabaya, Indonesia, June 18, 2005

54. F SaadThe role of testosterone in the Metabolic Syndrome Andrology Intensive Course, Hang Tuah University, Surabaya, Indonesia, June 19, 2005

55. F SaadDHEA treatment in the aging male Andrology Intensive Course, Hang Tuah University, Surabaya, Indonesia, June 20, 2005

56. F SaadThe role of testosterone in erectile function and dysfunction Andrology Intensive Course, Hang Tuah University, Surabaya, Indonesia, June 21, 2005

57. F SaadNebido – experience with a novel long-acting testosterone undecanoate Hypogonadism Centre of Excellence Meeting, London, UK, June 29, 2005

58. A Yassin and F Saad Does a long-acting testosterone injection (Nebido) have an impact on DHT?Poster, XVII World Congress of Sexology, Montréal, Canada, July 10-15,2005

59. A Yassin and F Saad Modulation of erectile function with long-acting i.m. testosterone injection (Nebido) in hypogonadal patientsModerated poster, XVII World Congress of Sexology, Montréal, Canada, July 10-15,2005

60. A Yassin and F Saad Changes in penile cavernosography and venous leakage under testosterone therapy in hypogonadal patients with ED, Case ReportModerated poster, XVII World Congress of Sexology, Montréal, Canada, July 10-15,2005

61. A Yassin and F Saad Comparison of the three PDE-5 inhibitors in the same populationXVII World Congress of Sexology, Montréal, Canada, July 10-15,2005

62. F SaadO Papel da Testosterona na Síndrome MetabólicaCongresso Brasileiro de Atualização em Endocrinologia e Metabologia, Aracaju, Brazil, July 26-30, 2005

63. A Yassin and F SaadAlterações na Cavernosografia e Dispersão Venosa do Pênis sob Terapia de Testosterona com Nebido® em Pacientes Hipogonádicos com Disfunção Erétil “Relato de Caso”VIII Congresso Brasileiro Sobre Inadequação Sexual, Belo Horizonte, Brazil, July 28-29, 2005

64. F SaadThe role of testosterone in erectile function and dysfunction Educational symposium, Asan Medical Center, Seoul, Korea, August 29, 2005

65. F SaadThe role of testosterone in erectile functionEducational symposium, Samsung Jeil Hospital, Seoul, Korea, August 30, 2005

66. F SaadThe role of testosterone in the metabolic syndrome Educational symposium, Lotte Hotel, Seoul, Korea, August 30, 2005

67. F SaadThe role of testosterone in the metabolic syndromeChonnam National University Medical School, Gwangju, Korea, August 31, 2005

68. F SaadMale hypogonadism: Is it a serious medical condition?Fireplace Talk, Hotel Intercontinental, Berlin, September 10, 2005

69. F SaadLong-acting testosterone undecanoate (TU) injection (Nebido®): The novel option for long-term treatment of testosterone deficiencyFireplace Talk, Hotel Intercontinental, Berlin, September 10, 2005

70. F SaadAndrology and ScheringSymposium Visit of Italian Andrologists, Schering AG, Berlin, September 16, 2005

71. F SaadGibt es Zusammenhänge zwischen dem metabolischen Syndrom und Testosteron?Hommage Internationales Andrologietraining, Oehningen, Germany, October 1, 2005

72. F SaadExperience with a novel, long-acting injection of testosterone undecanoate5th National Conference on Sexual Medicine, Sinaia, Romania, October 29, 2005

73. F SaadVieillissement de l’homme – signes cliniques et symptomes du déficit en testostérone2. Congrès International de la STRSI, Sousse, Tunisia, November 12, 2005

74. F SaadO Papel da Testosterona na Síndrome MetabólicaSimpósio Internacional Schering, São Paulo, Brazil, November 28, 2005

75. F SaadThe Physiological Role of Testosterone in Male Sexual FunctionVIII Congreso de la Sociedad Latinoamericana para el Estudio de la Impotencia y la Sexualidad, Punta del Este, Uruguay, December 2, 2005

76. F SaadTestosterontherapie beim Mann – wann und wie?Verein iranischer Ärzte, Zahnärzte, Tierärzte und Apotheker in Berlin, Berlin, Germany, January 27, 2006

77. F SaadClinical signs and symptoms of testosterone deficiency in the aging maleFireplace Talk, Hotel SAS Radisson, Berlin, Germany, March 04, 2006

78. F SaadEfficacy and safety of intramuscular testosterone undecanoateFireplace Talk, Hotel SAS Radisson, Berlin, Germany, March 04, 2006

79. F SaadEffekte von DHEA im ZNS: Depression, Libido, Neuroprotektion6th Conference of GSAAM, Duesseldorf, Germany, May 19, 2006

80. F SaadThe new alternative for long-term testosterone therapy: injectable testosterone undecanoate (Nebido®)Turkish Society of Urology, Antalya, Turkey, June 10, 2006

81. F SaadTreatment of male hypogonadism – Meet the expert meetingTurkish Society of Urology, Antalya, Turkey, June 11, 2006

82. F SaadEfficacy and safety of long-term intramuscular testosterone undecanoate (Nebido®)Round Table Discussion, Kuala Lumpur, Malaysia, August 07, 2006

83. F SaadEfficacy and safety of long-term intramuscular testosterone undecanoate (Nebido®)Round Table Discussion, Singapore, August 08, 2006

84. F SaadThe role of testosterone in the metabolic syndrome and erectile dysfunction2nd Congress of the Indonesian Association of Sexology and 1st INA International Symposium on Sexual Medicine, Surabaya, Indonesia, August 10, 2006

85. F SaadHormone deficiency in aging men: An update on testosterone treatmentSchering Nebido Launch Symposium at the 2nd Congress of the Indonesian Association of Sexology and 1st INA International Symposium on Sexual Medicine, Surabaya, Indonesia, August 11, 2006

86. F SaadEfficacy and safety of long-term intramuscular testosterone undecanoate (Reandron 1000®)Round Table Discussion, Sydney, Australia, August 14, 2006

87. F SaadEfficacy and safety of long-term intramuscular testosterone undecanoate (Reandron 1000®)Round Table Discussion, Melbourne, Australia, August 15, 2006

88. F Saad

Male hypogonadism: Choosing the right patient for testosterone therapySchering Nebido Launch Symposium, Bangkok, Thailand, August 17, 2006

89. F SaadTestosterone usage in ED patients: The role of co-morbiditiesSchering Nebido Symposium, Manila, Philippines, August 21, 2006

90. F SaadDHEA supplementation for the aging male8th Asian Congress of Urology, Nusa Dua, Bali, Indonesia, August 23, 2006

91. F SaadDoes testosterone have a role as first line treatment of hypogonadal men with erectile dysfunction? Current knowledge and perspectivesFireplace Talk, International Trade Center, Berlin, Germany, September 30, 2006

92. F SaadTestosterone Undecanoate (TU), the Long Lasting Alternative Therapy in Late Onset HypogonadismNebido Launch Symposium Turkey, Hilton Hotel, Istanbul, Turkey, October 10, 2006

93. F SaadTestosterone Undecanoate (TU), the Long Lasting Alternative Therapy in Late Onset HypogonadismNebido Launch Symposium Turkey, Hilton Hotel, Ankara, Turkey, October 11, 2006

94. F SaadEl papel de la testosterona en la obesidad visceral y en el síndrome metabólicoLVII Congreso Nacional de Urología, Puerto Vallarta, Mexico, November 16, 2006

95. F SaadNebido – a new treatment option for testosterone deficiencyNebido Launch Symposium Malaysia, Evergreen Hotel, Penang, Malaysia, January 12, 2007

96. F SaadTestosterone deficiency syndrome (TDS) – epidemiology and treatment benefitsNebido Launch Symposium Malaysia, Kuala Lumpur, Malaysia, January 13, 2007

97. F SaadTestosterone deficiency syndrome (TDS) – epidemiology and treatment benefitsNebido Launch Symposium Malaysia, Johor Bahru, Malaysia, January 14, 2007

98. F SaadThe metabolic syndrome and erectile dysfunction: testosterone may be a common denominatorSchering Satellite Symposium PASSM, Dubai, UAE, February 09, 2007

99. F SaadHormone deficiency in aging men: an update on testosterone treatmentPASSM, Dubai, UAE, February 10, 2007

100. F SaadThe aging male – an invention or reality?PASSM, Dubai, UAE, February 10, 2007

101. F Saad, A Yassin, A Haider, R ShabsighEffects of androgen deprivation on glycemic control and on biochemical cardiovascular risk factors in men with diabetesPASSM, Dubai, UAE, February 11, 2007

102. F SaadTestosterone and obesityPASSM, Dubai, UAE, February 11, 2007

103. F SaadDoes testosterone have a role as first-line treatment of hypogonadal men with erectile dysfunction? Current knowledge and perspectivesFireplace Talk, Crowne Plaza City Centre, Berlin, Germany, March 20, 2007

104. F SaadTestosterone treatment of erectile dysfunction: experience in 122 hypogonadal patients1st World Congress for Sexual Health, Sydney, NSW, Australia, April 16, 2007

105. F SaadErectile dysfunction, the metabolic syndrome, and testosterone deficiency – is there a link?1st World Congress for Sexual Health, Sydney, NSW, Australia, April 17, 2007

106. F SaadLong-term experience of up to 9.5 years with a long-acting formulation of testosterone undecanoate (TU) in substitution therapy of hypogonadal men1st World Congress for Sexual Health, Sydney, NSW, Australia, April 18, 2007

107. F SaadWhat do men think about male fertility control (MFC)?1st World Congress for Sexual Health, Sydney, NSW, Australia, April 17, 2007

108. F SaadSexual health is the gateway to men’s healthInaugural Address, Hang Tuah University, Surabaya, Indonesia, April 30, 2007

109. F SaadHormone replacement in the aging male – testosterone, growth hormone, and DHEACME Course Men’s Health, Surabaya, Indonesia, April 30, 2007

110. F SaadThe metabolic syndrome and male sexual dysfunctionCME Course Men’s Health, Surabaya, Indonesia, May 01, 2007

111. F Saad

Links between testosterone deficiency, metabolic syndrome and erectile dysfunction4th Congress of the Asian Pacific Society for the Study of the Aging Male, Nusa Dua, Bali, Indonesia, May 03, 2007

112. F SaadTestosterone adds on to the therapeutic effects of exercise and diet in diabetes type 24th Congress of the Asian Pacific Society for the Study of the Aging Male, Nusa Dua, Bali, Indonesia, May 04, 2007

113. F Saad, L Gooren, A Haider, A YassinEffects of testosterone administration on variables of the metabolic syndrome4th Congress of the Asian Pacific Society for the Study of the Aging Male, Nusa Dua, Bali, Indonesia, May 04, 2007

114. F Saad, L Gooren, A Haider, A YassinEffects of androgen deprivation on glycemic control and on biochemical cardiovascular risk factors in men with diabetes4th Congress of the Asian Pacific Society for the Study of the Aging Male, Nusa Dua, Bali, Indonesia, May 04, 2007

115. F SaadHormone deficiency in aging men – an update on testosterone treatment4th Congress of the Asian Pacific Society for the Study of the Aging Male, Nusa Dua, Bali, Indonesia, May 04, 2007

116. F SaadAndrogen therapy – advantages and disadvantages4th Congress of the Asian Pacific Society for the Study of the Aging Male, Nusa Dua, Bali, Indonesia, May 04, 2007

117. F SaadMale aging – clinical signs and symptoms of testosterone deficiency4th Congress of the Asian Pacific Society for the Study of the Aging Male, Nusa Dua, Bali, Indonesia, May 04, 2007

118. F SaadThe aging male – an invention or reality?4th Congress of the Asian Pacific Society for the Study of the Aging Male, Nusa Dua, Bali, Indonesia, May 04, 2007

119. F SaadComparison of the effects of testosterone gel with parenteral testosterone undecanoate on features of the metabolic syndrome4th Congress of the Asian Pacific Society for the Study of the Aging Male, Nusa Dua, Bali, Indonesia, May 04, 2007

120. F SaadTestosterone and obesity4th Congress of the Asian Pacific Society for the Study of the Aging Male, Nusa Dua, Bali, Indonesia, May 05, 2007

121. F SaadWhat do men think about male fertility control (MFC)?4th Congress of the Asian Pacific Society for the Study of the Aging Male, Nusa Dua, Bali, Indonesia, May 05, 2007

122. F SaadSexual health is the gateway to men’s healthBayer Schering Pharma Symposium, Chengdu, China, May 10, 2007

123. F SaadThe role of androgens in erectile functionBSP Symposium “Erectile dysfunction: present and future”, Birmingham, UK, June 09, 2007

124. F SaadThe role of testosterone replacement in the management of EDBSP Symposium “Erectile dysfunction: present and future”, Birmingham, UK, June 09, 2007

125. F SaadTestosterone deficiency syndrome – epidemiology and treatment benefitsEducational Symposium, Singapore General Hospital, Singapore, August 16, 2007

126. F SaadTestosterone deficiency syndrome – epidemiology and treatment benefitsNebido Soft Launch Symposium, Bayer Schering Office, Singapore, August 17, 2007

127. F SaadPersonal experience and long-term experience and safety of NebidoNebido Launch Symposium, Fullerton Hotel Singapore, Singapore, August 18, 2007

128. F SaadHormone replacing in the aging male and risk factorsCongress of the Indonesian Society of Andrology, Manado, Indonesia, August 25, 2007

129. F SaadTestosterone, inflammation and atherosclerosisCongress of the Indonesian Society of Andrology, Manado, Indonesia, August 25, 2007

130. F SaadMetabolic syndrome and testosterone25th Congress of the Syrian Urological Society, Aleppo, Syria, September 06, 2007

131. F SaadTestosterone and prostate cancer25th Congress of the Syrian Urological Society, Aleppo, Syria, September 06, 2007

132. F Saad

Testosterone deficiency syndrome (TDS) and the role of comorbid conditionsBayer Schering Pharma Symposium, Almaty, Kazakhstan, September 13, 2007

133. F SaadTestosterone, inflammation, and atherosclerosisBayer Schering Pharma Symposium, Moscow, Russian Federation, September 24, 2007

134. F SaadTestosterone, inflammation, and atherosclerosisBayer Schering Pharma Symposium, Kazan, Russian Federation, September 25, 2007

135. F SaadClinical signs and relevance of hypogonadismTestosterone Expert Meeting, Hotel Intercontinental, Berlin, Germany, September 29, 2007

136. F SaadRole of testosterone as first-line treatment of hypogonadal men with erectile dysfunction? Current knowledge and perspectivesTestosterone Expert Meeting, Hotel Intercontinental, Berlin, Germany, September 29, 2007

137. F SaadShould testosterone deficiency and ED be considered as components of the metabolic syndrome?Bayer Schering Pharma Symposium at 11th Biennial Meeting of the Asia Pacific Society for Sexual Medicine , Jeju, Korea, October 08, 2007

138. F SaadDose effects of testosterone on features of the metabolic syndrome: parenteral testosterone undecanoate compared with testosterone gel11th Biennial Meeting of the Asia Pacific Society for Sexual Medicine , Jeju, Korea, October 08, 2007

139. F SaadWhat is the future of the testosterone deficiency syndrome?11th Biennial Meeting of the Asia Pacific Society for Sexual Medicine , Jeju, Korea, October 09, 2007

140. M Zitzmann, F Saad, E NieschlagPharmacogenetics and body mass modulate safety of testosterone substitution: experience of 118 treatment-years with a long-acting formulation of testosterone undecanoate11th Biennial Meeting of the Asia Pacific Society for Sexual Medicine , Jeju, Korea, October 09, 2007

141. F Saad, L Gooren, A Haider, A YassinHigh levels of dihydrotestosterone in hypogonadal men decline upon normalization of testosterone levels

11th Biennial Meeting of the Asia Pacific Society for Sexual Medicine , Jeju, Korea, October 09, 2007

142. F Saad, A Heufelder, L GoorenThe favourable effects of exercise and dietary modification in hypogonadal men with type 2 diabetes mellitus are enhanced by testosterone administration11th Biennial Meeting of the Asia Pacific Society for Sexual Medicine , Jeju, Korea, October 09, 2007

143. F Saad, S Freude, D Huebler, M Oettel, M Schubert, L Gooren, F JockenhoevelEfficacy and safety of the long-acting parenteral testosterone undecanoate: a four year follow-up11th Biennial Meeting of the Asia Pacific Society for Sexual Medicine , Jeju, Korea, October 09, 2007

144. F SaadBiological production and effects of testosteroneTestosterone Therapy Expert Workshop, Hotel Hilton Paddington, London, UK, November 16, 2007

145. F SaadHypogonadism and ED – the role of testosterone therapyTestosterone Therapy Expert Workshop, Hotel Hilton Paddington, London, UK, November 17, 2007

146. F Saad, A Yassin, A HaiderAsociación entre la terapia de privación de andrógeno y el deterioro del control glucémico y los factores de riesgo cardiovascular en hombres con diabetes mellitus tipo 2IX congreso de la Sociedad Latinoamericana de Medicina Sexual, Lima, Peru, November 29, 2007

147. F Saad¿La deficiencia de testosterona y DE deben ser componentes del síndrome metabólico?IX congreso de la Sociedad Latinoamericana de Medicina Sexual, Lima, Peru, November 29, 2007

148. F Saad, L Gooren, A Haider, A YassinLa administración durante 12 meses de una preparación de larga duración de undecanoato de testosterona (Nebido) mejora las mediciones de la disfunción erectile y el síndrome metabólicoIX congreso de la Sociedad Latinoamericana de Medicina Sexual, Lima, Peru, November 30, 2007

149. F SaadEl undecanoato de testosterona de larga duración es más efectivo que el gel de testosterona para mejorar las características del síndrome metabólico en hombres que padecen hipogonadismo

IX congreso de la Sociedad Latinoamericana de Medicina Sexual, Lima, Peru, November 30, 2007

150. M Zitzmann, F Saad, E NieschlagLa seguridad y eficacia de una formula de larga duración de undecanoato de testosterona está modulada por la masa corporal y variables farmacogenéticas: experiencia de 118 años-tratamiento de sustitución de testosteronaIX congreso de la Sociedad Latinoamericana de Medicina Sexual, Lima, Peru, November 30, 2007

151. T. Minnemann, F. Saad, M. Schubert, D. Huebler, D. Rouskova, I Gouni-Berthold, C. Schumann, A. Christoph, M. Oettel, M. Ernst, U. Mellinger, W. Krone, L. Gooren, F. JockenhoevelComparación de la seguridad y eficacia de una formula nueva de larga duración de undecanoato de testosterona con enantato en hombres con hipogonadismoIX congreso de la Sociedad Latinoamericana de Medicina Sexual, Lima, Peru, November 30, 2007

152. F Saad, L Gooren, A Haider, A Yassin15 meses de tratamiento con undecanoato de testosterona (Nebido) mejoraron las características del síndrome metabólico IX congreso de la Sociedad Latinoamericana de Medicina Sexual, Lima, Peru, November 30, 2007

153. S Freude, D Huebler, M Oettel, M Schubert, L Gooren, F Jockenhoevel, F SaadEficacia y seguridad del undecanoato de testosterona de larga duración a lo largo de 4 añosIX congreso de la Sociedad Latinoamericana de Medicina Sexual, Lima, Peru, November 30, 2007

154. F Saad, L Gooren, A Haider, A YassinLos niveles altos en plasma de dihidrotestosterona disminuyen en hombres con hipogonadismo después de l sustitución de testosteronaIX congreso de la Sociedad Latinoamericana de Medicina Sexual, Lima, Peru, November 30, 2007

155. YA Tishova, GZ Mskhalaya, F Saad, SY KalinchenkoEl tratamiento con testosterona con undecanoato de testosterona de larga duración en hombres con hipogonadismo de inicio tardío y los niveles reducidos en suero de interleuquina 6, factor de necrosis tumoral alfa y protein C reactiva del síndrome metabólico IX congreso de la Sociedad Latinoamericana de Medicina Sexual, Lima, Peru, November 30, 2007

156. F SaadObesity, chronic inflammation and endothelial function6th Biennial Congress of Africa Gulf Society for Sexual Medicine, Dubai, UAE, December 14, 2007

157. F SaadThe link between metabolic syndrome and testosteroneAndrološki simpozij endokrinologov, diabetologov in urologov, Bled, Slovenia, January 11, 2008

158. F SaadBehandlung eines Testosteronmangelsyndroms mit Testosteron im Kontext des KomorbiditätenkonzeptsReferententreffen Männergesundheit-Urologie, Frankfurt, Germany, January 19, 2008

159. F SaadAktueller Überblick über klinische Daten zu TestosteronGerman Advisory Board Meeting, Leverkusen, Germany, February 16, 2008

160. F SaadEfectos de la testosterona sobre la disfunción eréctil y el síndrome metabólicoNebido Launch Symposium Guatemala, Guatemala City, Guatemala, February 19, 2008

161. F SaadEfectos de la testosterona sobre la disfunción eréctil y el síndrome metabólicoNebido Launch Symposium Costa Rica and El Salvador, San José, Costa Rica, February 20, 2008

162. F SaadTestosterone Administration in Addition to Exercise and Diet Enhances Therapeutic Effects in Men with Type 2 Diabetes with Subnormal Testosterone Levels6th World Congress on the Aging Male, Tampa, Florida, USA, February 23, 2008

163. F SaadBiological production and effects of testosteroneTestosterone therapy expert workshop, Newcastle, UK, February 29, 2008

164. F SaadHypogonadism and ED – the role of testosterone therapyTestosterone therapy expert workshop, Newcastle, UK, March 01, 2008

165. F SaadBiological production and effects of testosteroneSymposium on recent developments and discussions in testosterone therapy, London, UK, March 07, 2008

166. F SaadHypogonadism and ED – the role of testosterone therapySymposium on recent developments and discussions in testosterone therapy, London, UK, March 08, 2008

167. F Saad

New aspects in the therapy of testosterone deficiency syndrome – can it be the key to metabolic syndrome in men?Impiana Casuarina Hotel, Ipoh, Malaysia, March 14, 2008

168. F SaadNew aspects in the therapy of testosterone deficiency syndrome – can it be the key to metabolic syndrome in men?Ipoh Country Club, Ipoh, Malaysia, March 15, 2008

169. F SaadNew aspects in the therapy of testosterone deficiency syndrome – can it be the key to metabolic syndrome in men?Equatorial Hotel, Melaka, Malaysia, March 15, 2008

170. F SaadNew aspects in the therapy of testosterone deficiency syndrome – can it be the key to metabolic syndrome in men?The Royale Bintang Hotel, Seremban, Malaysia, March 16, 2008

171. F SaadCharacteristics and effects of injectable testosterone undecanoate – a new option for testosterone treatmentBayer Schering Pharma Symposium, 20th Saudi Urology Conference, Al Khobar, Saudi Arabia, March 20, 2008

172. F SaadCharacteristics and effects of injectable testosterone undecanoate – a new option for testosterone treatmentMarriott Hotel, Riyadh, Saudi Arabia, March 21, 2008

173. F SaadCharacteristics and effects of injectable testosterone undecanoate – a new option for testosterone treatmentMarriott Hotel, Jeddah, Saudi Arabia, March 22, 2008

174. F SaadThe history of testosterone therapy and modern treatment modalitiesXth Congress of the Syrian Urological Society, Hama, Syria, April 18, 2008

175. F SaadHormonal male contraception – where do we stand today?Xth Congress of the Syrian Urological Society, Hama, Syria, April 18, 2008

176. F SaadDisfunção Erétil - O Portal para a Saúde Masculina – Trate a DE e Verifique a T Projeto Integrado Saúde Masculina (PRISMA), São Paulo, Brasil, May 10, 2008

177. F SaadBiological production and effects of testosteroneSymposium on recent developments and discussions in testosterone therapy, London, UK, May 14, 2008

178. F SaadClinical relevance of hypogonadismSymposium on recent developments and discussions in testosterone therapy, London, UK, May 15, 2008

179. F SaadTestosterone deficiency and erectile dysfunctionSymposium on recent developments and discussions in testosterone therapy, London, UK, May 15, 2008

180. F SaadThe role of testosterone, the metabolic syndrome and erectile dysfunction in men’s healthBayer Schering Pharma Symposium, Skopje, Makedonia, May 27, 2008

181. F SaadThe role of testosterone, the metabolic syndrome and erectile dysfunction in men’s healthBayer Schering Pharma Symposium, Belgrade, Serbia, May 28, 2008

182. F SaadMetabolic syndrome and obesity are significant risk factors in male sexual dysfunction and hormone deficiencySiriraj University Hospital Symposium, Bangkok, Thailand, June 04, 2008

183. F SaadSexual health in aging men – how to promote sexual health in general practiceSiriraj University Hospital Symposium, Bangkok, Thailand, June 04, 2008

184. F SaadWhat can we learn from androgen deprivation therapy?Asia Pacific Men’s Healthcare Expert Workshop, Shangri-La Hotel, Chiang Mai, Thailand, June 07, 2008